You searched for: irinotekaanravi (Estniska - Engelska)

üksikravimina patsientidel, kellel oksaliplatiin - ja irinotekaanravi ei ole andnud tulemusi ning kes ei talu irinotekaani.
as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.

10 Ühte kliinilisse uuringusse (avf2192g) kaasati metastaatilise kolorektaalse vähiga patsiendid, kes ei olnud irinotekaanravi kandidaadid.
in one clinical trial, avf2192g, patients with metastatic colorectal cancer who were not candidates for treatment with irinotecan were included.

kombinatsioonis irinotekaani sisaldava kemoteraapiaga, esmavaliku ravina kombinatsioonis folfox-iga, üksikravimina patsientidel, kellel oksaliplatiin- ja irinotekaanravi ei ole andnud tulemusi ning kes ei talu irinotekaani.
in combination with irinotecan-based chemotherapy, in first-line in combination with folfox, as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.

see oli ii faasi randomiseeritud topeltpime aktiivse võrdlusravimiga kontrollitud kliiniline uuring, mis hindas avastin’i ja 5-fu/fa kombinatsiooni efektiivsust ja ohutust metastaatilise kolorektaalse vähi esmase ravina patsientidel, kes ei olnud esmavaliku irinotekaanravi optimaalsed kandidaadid.
this was a phase ii randomised, double-blind, active-controlled clinical trial evaluating the efficacy and safety of avastin in combination with 5-fu/fa as first-line treatment for metastatic colorectal cancer in patients who were not optimal candidates for first-line irinotecan treatment.